Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mitochondrial localization of the membrane proteins Bcl-2 and Bcl-x(L) is essential for their anti-apoptotic function. Here we show that mitochondrial
FK506-binding protein 38
(
FKBP38
), unlike FKBP12, binds to and inhibits
calcineurin
in the absence of the immunosuppressant FK506, suggesting that
FKBP38
is an inherent inhibitor of this phosphatase.
FKBP38
is associated with Bcl-2 and Bcl-x(L) in immunoprecipitation assays and colocalizes with these proteins in mitochondria; in addition, the expression of
FKBP38
mutant proteins induces a marked redistribution of Bcl-2 and Bcl-x(L). Overexpression of
FKBP38
blocks apoptosis, whereas functional inhibition of this protein by a dominant-negative mutant or by RNA interference promotes apoptosis. Thus,
FKBP38
might function to inhibit apoptosis by anchoring Bcl-2 and Bcl-x(L) to mitochondria.
...
PMID:Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. 1251 82
The microbial peptidomacrolide FK506 affects many eukaryotic developmental and cell signaling programs via
calcineurin
inhibition. Prior formation of a complex between FK506 and intracellular FK506-binding proteins (FKBPs) is the precondition for the interaction with
calcineurin
. A puzzling difference has emerged between the mammalian multidomain protein
hFKBP38
and other FKBPs. It was shown that
hFKBP38
not only binds to
calcineurin
but also inhibits the
protein phosphatase
activity of
calcineurin
on its own [Shirane, M. and Nakayama, K.I. (2003) Nature Cell Biol. 5, 28-37]. Inherent
calcineurin
inhibition by
hFKBP38
would completely eliminate the need for FK506 in controlling many signal transduction pathways. To address this issue, we have characterized the functional and physical interactions between
calcineurin
and
hFKBP38
. A recombinant
hFKBP38
variant and endogenous
hFKBP38
were tested both in vitro and in vivo. The proteins neither directly inhibited
calcineurin
activity nor affected NFAT reporter gene activity in SH-SY5Y and Jurkat cells. In addition, a direct physical interaction between
calcineurin
and
hFKBP38
was not detected in co-immunoprecipitation experiments. However,
hFKBP38
indirectly affected the subcellular distribution of
calcineurin
by interaction with typical
calcineurin
ligands, as exemplified by the anti-apoptotic protein Bcl-2. Our data suggest that
hFKBP38
cannot substitute for the FKBP/FK506 complex in signaling pathways controlled by the
protein phosphatase
activity of
calcineurin
.
...
PMID:A reassessment of the inhibitory capacity of human FKBP38 on calcineurin. 1575 46